Randomized Multicenter Phase III Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients (HILARIA)
Latest Information Update: 12 Sep 2023
At a glance
- Drugs AI 201901 (Primary) ; Azelastine
- Indications Allergic rhinitis
- Focus Registrational; Therapeutic Use
- Acronyms HILARIA
- Sponsors Abdi Ibrahim Pharmaceuticals
- 06 Sep 2023 Status changed from recruiting to completed.
- 17 May 2022 Planned End Date changed from 15 Feb 2022 to 15 Dec 2022.
- 17 May 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Nov 2022.